Select Your Region
America
Europa
Afrika
Weltweit
Eine Studie zur Beurteilung der PD-L1-Expression (PD-L1: programmierter Zelltod-Ligand 1) in zytologischen gegenüber histologischen Lungenkrebsproben
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
- Krebs
- Lungenkrebs
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Abgeschlossen
Diese Studie läuft in
Stadt
- Göttingen
Studien-ID:
NCT03092739 MO29978
Studienzusammenfassung
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT03092739,MO29978
Studien-ID
PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
Treatments
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
Condition
Official Title
A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens
Einschlusskriterien
All
Gender
No
Healthy Volunteers
Inclusion Criteria
- Samples must have been collected in a manner that is compliant with local ethics committee guidance
- Samples must originate from participants diagnosed with NSCLC or SCLC
- Participants must have a pair of at least one cytological and one histological specimen that: Both originate from inside the thorax or from the same ex-thoracic site; Are confirmed to have been collected within a window no more than 6 weeks apart from each other; and are in compliance with the protocol defined sample requirements for histological and cytological specimens
Exclusion Criteria
- Immune checkpoint inhibitor therapy from 4 weeks prior to collection of the first tumor sample until collection of the second matched sample
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
